Loading
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
Latest quote
¥1,069
−¥29.00 · -2.64%
Regular session · JST · Market data may be delayed.
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
Day range
Current ¥1,069
52-week range
Current ¥1,069
Regular session · JST · Market data may be delayed.
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
Day range
Current ¥1,069
52-week range
Current ¥1,069
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 18.52B JPY | 46.68B JPY | 28.71B JPY | 26.85B JPY | 9.42B JPY |
| Cost of goods sold | 11B JPY | 12.52B JPY | 11.85B JPY | 9.04B JPY | 2.46B JPY |
| Gross profit | 7.52B JPY | 34.16B JPY | 16.86B JPY | 17.81B JPY | 6.96B JPY |
| Research and development | 5.02B JPY | 4B JPY | 3.16B JPY | 2.92B JPY | 1.65B JPY |
| Selling, general, and administrative | 7.47B JPY | 8.59B JPY | 6.67B JPY | 5.83B JPY | 2.59B JPY |
| Operating expenses | 12.5B JPY | 12.76B JPY | 9.69B JPY | 8.47B JPY | 2.91B JPY |
| Interest income | 242.61M JPY | 15.84M JPY | 6.17M JPY | 1.33M JPY | 283K JPY |
| Interest expense | 500.31M JPY | 288.06M JPY | 231.86M JPY | 190.09M JPY | — |
| Depreciation and amortization | 2.13B JPY | 2.25B JPY | 2.43B JPY | 1.97B JPY | 633.01M JPY |
| Operating income | −4.97B JPY | 21.39B JPY | 7.18B JPY | 9.35B JPY | 4.05B JPY |
| Net income | −3.75B JPY | 15.01B JPY | 3.04B JPY | 7.55B JPY | 2.57B JPY |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 28, 2017 | 2:1 | — | — |
Stock split | Jun 26, 2015 | 4:1 | — | — |
Effective Jun 28, 2017
2:1
Effective Jun 26, 2015
4:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T302.17M0.01%2.9T JPY0.05%¥421.6+0.12%
Vanguard Total International Stock ETFVXUS8.28M0.00%646.2B USD0.05%$88.41+0.50%
iShares Core MSCI EAFE ETFIEFA5.68M0.00%193.86B USD0.07%$101.08+0.13%
Vanguard FTSE Developed Markets ETFVEA5.54M0.00%315B USD0.03%$73.76+0.44%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS2.57M0.02%13.6B USD0.06%$161.34+0.42%
iShares MSCI EAFE Small-Cap ETFSCZ2.35M0.02%13.11B USD0.40%$87.57+0.10%
Schwab International Small-Cap Equity ETFSCHC1.42M0.02%5.68B USD0.06%$51.62+0.27%
iShares Core MSCI Total International Stock ETFIXUS1.31M0.00%60.45B USD0.07%$98.71+0.57%iShares Core TOPIX ETF1475.TVanguard Total International Stock ETFVXUSiShares Core MSCI EAFE ETFIEFAVanguard FTSE Developed Markets ETFVEAVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares MSCI EAFE Small-Cap ETFSCZSchwab International Small-Cap Equity ETFSCHCiShares Core MSCI Total International Stock ETFIXUSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
